Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Non-Clinicians / Medical Office Support Staff / Industry Participants

In order to maintain the clinical nature of the conference, nonclinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff; guests, spouses, friends, and/or family members—may not attend PAINWeekEnd.

Venue

Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

Hyatt Regency Baltimore Inner Harbor
300 Light Street
Baltimore, MD 21202

View hotel website >>

Directions

Get Directions using Google Maps

Agenda

Faculty and courses are subject to change. Please refer to the online agenda below for the most recent course descriptions.

To view the agenda below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

*not certified for credit

Saturday, September 28, 2019

  • REGISTRATION & EXHIBITS

    Coffee will be served.

  • Chronic Pain Assessment

    Effective clinical interviewing and pain assessment are critical to the appropriate diagnosis and management of pain. In this presentation, attendees will learn how to apply principles of effective communication and also ascertain how to evaluate available assessment tools.

    • UAN: 0530-0000-19-235-L01-P
    • AANP Rx Hours: 0.00
  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Refreshments will be served.

    Sponsored by Legally Mine.

  • BREAK & EXHIBITS

  • 3's Company: COX-2 Inhibitors, Medicinal Marijuana, and Opioid Prescribing

    There is much controversy around many aspects of pain treatment, and compelling arguments have focused on both sides of the fence regarding appropriate opioid use and prescribing, legalization of marijuana, and the safety of cox-2 inhibitors. In all  3 cases, there are issues associated with strong positions, although the evidence, when put into practice, is less black and white. For each topic, we will evaluate current literature and debate the clinical, legal, and ethical controversies surrounding recent developments in pain management. Attendees will get a better understanding as presenters debate evidence based application of the cdc guidelines in various clinical settings, evaluate clinical and ethical concerns regarding marijuana for medicinal or recreational use, and take a critical look at the literature and its application when using cox-2 inhibitors for treating pain.

    • UAN: 0530-0000-19-050-L01-P
    • AANP Rx Hours: 0.00
  • The Regulatory Agency Will See You Now

    Despite high prevalence and seemingly continuous attention, the clinical challenges associated with assessing, treating, and managing patients with chronic pain continue to persist. Many different forces are at play and responsible for this frequently frustrating situation and, as is often the case, the person with the most at risk is the patient with chronic pain. There is no deficit of opinions for possible solutions to this problem. In fact, the number of potential solutions seems to increase each year, all with the intent of helping pain care be more safe and effective, and most trying to stem the negative consequences of abuse, misuse, and diversion of prescription pain medications. Clinicians have had to juggle these good intentions along with the fear of regulatory scrutiny. This course will present and detail the variety of current regulatory forces that need to be considered in clinical practice; how they can potentially impact clinical decisions regarding chronic pain; and how they can be negotiated. A number of regulatory agencies are now “sitting at the pain management table” for the foreseeable future and it is critical to navigate the waters without sacrificing that most important stakeholder: the patient.

    • UAN: 0530-0000-19-014-L01-P
    • AANP Rx Hours: 0.40
  • FACULTY Q&A

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Lunch will be served.

    Sponsored by Teva Pharmaceuticals

  • Precise Prescribing: Applying the Science of Pain to Treatment Decisions

    Appropriate prescribing for acute and chronic pain in the midst of the opioid epidemic requires a strong knowledge of pain pathways and underlying mechanisms to optimize treatment decision-making. This symposium will integrate 3D modeling to bring pain and addiction mechanisms to life in order to promote a better understanding of evolving pain management strategies. Faculty will provide best practice strategies for the clinical assessment and management of acute and chronic pain aligned to supporting evidence and recommendations to guide safe and effective pharmacological and nonpharmacologic treatment choices.

    Presented by CME Outfitters and USF Health. Supported by an educational grant from Johnson & Johnson.

  • BREAK & EXHIBITS

  • The 411 on Nonprescription Analgesics: When to Hold ‘Em, When to Fold ‘Em

    Pain is the number one reason why patients seek advice from their pharmacist or primary care provider. Patients very often seek to use a nonprescription analgesic to self-treat a painful complaint, yet often do not understand the exclusions to self-treatment or how to select the best analgesic. Participants in this presentation will learn what nonprescription analgesics are available, indications for use, appropriate dosing and duration of therapy, appropriateness of candidates, and how to monitor and educate patients about their nonprescription analgesic. At this presentation, participants will learn the mechanism of action, indications, adverse effects, and precautions of oral and topical nonprescription analgesics, along with patient counseling points when recommending a nonprescription analgesic.

    • UAN: 0530-0000-19-051-L01-P
    • AANP Rx Hours: 0.70
  • The Other Opioid Crisis: Heroin and Fentanyl

    There is a significant amount of media, political, and public attention paid to the opioid crisis/opioid epidemic in the United States today. With the seemingly ever-increasing number of opioid-related overdoses and fatalities, there has been a feverish push by stakeholders to diminish the amount of opioids prescribed in order to help stem these worrisome trends. Unfortunately, there may be a lack of focus regarding the true definition and characterization of the opioid epidemic. There may also be a rush to judgment about the role of appropriately prescribed opioid analgesics in the addiction crisis we face today as well. This presentation will discuss the roles and statistics of both prescription and illicit opioids (namely heroin and fentanyl) in today’s “opioid overdose epidemic” with the intention of clarifying important differences and similarities between these competing epidemics including concerns and clinical considerations specific to each of them. Additionally, this program will examine and identify how these medications and drugs share potentially tragic adverse effect profiles in many cases. However, it is important for clinicians to make sure that appropriate chronic pain patients that may be candidates for opioid analgesic therapy aren’t penalized, and still get the treatment that they deserve.

    • UAN: 0530-0000-19-013-L01-P
    • AANP Rx Hours: 0.00

SPONSORED PROGRAMS

To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!